GeneDx Slides Premarket as Q4 Revenue Outlook Lands Well Below Consensus
WGS sits 80% above its 52-week low of $32.21 on elevated volume (2.5× avg).
Summary
GeneDx guided Q4 adjusted revenue to about $135M, roughly $7.6M below the $142.6M FactSet consensus, and the stock fell in premarket trading. Q3 itself was mixed: revenue of $123.1M edged past consensus by about $0.2M with 5% year-over-year growth, but the GAAP loss per share of $0.41 missed by $0.03 and the net loss widened about 62% to $12.3M. Gross margin slipped to roughly 70% from about 72% a year ago, even as exome and genome test revenue grew about 12% to $110.4M. The company reiterated its full-year revenue outlook of $475M-$490M, so the soft Q4 guide implies the growth deceleration is back-end loaded rather than a cut to the annual range. The setup matters because GeneDx is still burning cash — the Q3 10-Q showed $72.0M of nine-month operating cash burn against $170.1M of liquidity — so a slower revenue ramp pressures the path to sustained profitability.
At the time of this announcement, WGS was trading at $58.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $32.21 to $170.87. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Seeking Alpha.